Bifidobacterium longum Cell Wall Fraction for Respiratory Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for respiratory viral infections, such as those caused by influenza, rhinovirus, and RSV, often lead to excessive immune responses that result in immunopathology and secondary bacterial infections, particularly in susceptible individuals like those with COPD, asthma, or obesity, as they fail to effectively manage Type I interferon responses and promote damaging inflammation.
Innovation Solution
A cell wall fraction isolated from Bifidobacterium longum is used to attenuate the IP-10 response, enhance Type III interferon responses, and suppress Type I interferon responses, thereby reducing immunopathology and promoting anti-viral defense without inducing excessive inflammation, which can be administered as a nasal spray or incorporated into food products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Type I interferon responses are activated to clear viral infection, then anti-viral defense is enhanced, but pro-inflammatory damage and immunopathology increase
Solution Approach 1:
The Bifidobacterium longum cell wall fraction acts as an intermediary substance that modulates the immune response. It selectively enhances Type III interferon production while suppressing Type I interferon-mediated inflammation, thereby mediating between viral clearance and immunopathology prevention. The cell wall fraction contains specific components that interact with immune cells to achieve this balanced response.
Solution Approach 2:
The invention changes the parameter profile of the immune response by shifting the interferon type ratio. Instead of the conventional Type I-dominant response, the cell wall fraction promotes a Type III-dominant response pattern, which has different biological effects - providing antiviral protection without the same level of pro-inflammatory damage.
2Object-generated harmful factors
If corticosteroids are administered to reduce inflammation, then immunopathology is decreased, but viral clearance and secondary bacterial infection prevention are inhibited
Solution Approach 1:
The cell wall fraction changes the qualitative parameter of the immune response by inducing Type III interferon production, which has anti-viral activity without the strong pro-inflammatory effects of Type I interferon. This natural modulation achieves the therapeutic effect without the immunosuppressive side effects of corticosteroids.
Solution Approach 2:
The invention converts the harmful overactive Type I interferon response into a beneficial Type III interferon response. The cell wall fraction redirects the immune system's antiviral mechanism toward a less damaging pathway, effectively converting the harmful inflammatory response into a protective but non-damaging response.
3Reliability
If high levels of bifidobacteria are ingested to ensure probiotic effect, then gastrointestinal survival is improved, but the complexity of ensuring sufficient viable count is increased
Solution Approach 1:
The invention extracts the active immunomodulatory components from the Bifidobacterium longum cells, specifically the cell wall fraction. This extraction eliminates the need to deliver large numbers of viable bacteria while preserving the therapeutic effect. The cell wall fraction can be produced, stabilized, and delivered more easily than live bacteria.
Solution Approach 2:
The cell wall fraction serves as a stable, non-living alternative to viable bacteria. It does not require the complex conditions needed to maintain live bacterial cultures during storage and delivery, making the product more stable and easier to manufacture while maintaining therapeutic efficacy.
Data Source
AI summary
Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.